ATF-SAP

ATF-SAP is a recombinant fusion protein composed of the human amino-terminal fragment (ATF) of the urokinase-type plasminogen activator (uPA) and the plant-derived ribosome-inactivating protein saporin (SAP). It was developed to target and selectively kill cancer cells over-expressing the urokinase-type plasminogen activator receptor (uPAR). Upon binding to uPAR on the cell surface, ATF mediates internalization of the fusion protein, delivering saporin into the cell where its ribosome-inactivating activity induces cell death. ATF-SAP shows potent cytotoxicity against uPAR-expressing tumor cells in vitro at nanomolar concentrations and demonstrates antitumoral effects in vivo with limited toxicity to non-target cells. Its main therapeutic application under investigation is for aggressive tumors, particularly those with elevated uPAR expression such as certain bladder, breast, and hematological cancers[1][2][3].

Other names

ATF-SAP